April and May have been busy. We had a strong showing at ISPOR; it was great to see so many customers and colleagues in-person in DC! We added an industry luminary to our strategic advisory board, shared our perspective on high-validity RWE with other life sciences leaders on Pharmaceutical Executive, and contributed an article to Healthcare IT Today on bias in healthcare AI. Next up, Verantos will discuss early findings of the FDA-sponsored TRUST demonstration project at the 2022 BIO International Convention and chair a panel at the DIA Global Annual Meeting in Chicago.

Company News


Verantos, Amgen, and Lundbeck present at ISPOR

At ISPOR 2022 in Washington DC, Verantos led a forum in front of a standing room-only crowd. Panelists from Amgen, Lundbeck, and Beth Israel Lahey Health discussed the importance of high-validity real-world evidence and its increasing role in the decision-making process for payers, regulators, and providers. If you were unable to join the session, we’ve shared a recording.

Verantos logo

Frank Williams joins Verantos′ strategic advisory board

Verantos announced the appointment of Frank Williams to its strategic advisory board. Mr. Williams is the chairman and co-founder of Evolent Health and previously served as the company’s CEO.

Verantos provides RWE leadership in CEO roundtable

Verantos joined eight other life sciences executives to discuss the ongoing advancement of real-world data (RWD) and real-world evidence (RWE) as critical components of the life sciences industry.

Healthcare IT Today features Anand Shroff

Verantos President Anand Shroff shared sources of bias in artificial intelligence and some of the ways Verantos works to minimize its impact on RWE generation.

Verantos to present early findings from TRUST at BIO

Verantos will present early findings from the FDA-sponsored TRUST study, an FDA demonstration project, at the BIO International Convention in San Diego.

  • FDA’s RWE Grantees: One Year On
  • Monday, June 13 from 1pm – 2pm

Visit us at DIA – booth #2233

At the DIA 2022 Global Annual Meeting in Chicago, Verantos will hold a panel discussion on distilling to practice research-grade, real-world evidence. Joining us will be Cathy Critchlow, Vice President of R&D Data Strategy at Amgen and John Concato, Associate Director for Real-World Evidence Analytics, OMP, CDER at FDA.

  • Regulatory-Grade Real-World Evidence: Distilling to Practice
  • Tuesday, June 21 from 2pm – 3pm

Want to receive this newsletter in your inbox?